Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV, Single Arm Study of Safety and Efficacy of Everolimus in Chinese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Not Requiring Immediate Surgery

Next Previous
Trial Profile

Phase IV, Single Arm Study of Safety and Efficacy of Everolimus in Chinese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Not Requiring Immediate Surgery

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2019

At a glance

  • Drugs Everolimus (Primary)
  • Indications Angiomyolipoma
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 11 Jan 2019 Planned End Date changed from 29 Dec 2021 to 6 Jan 2022.
    • 11 Jan 2019 Planned primary completion date changed from 29 Dec 2021 to 6 Jan 2022.
    • 02 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top